MXPA03008134A - Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion. - Google Patents

Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.

Info

Publication number
MXPA03008134A
MXPA03008134A MXPA03008134A MXPA03008134A MXPA03008134A MX PA03008134 A MXPA03008134 A MX PA03008134A MX PA03008134 A MXPA03008134 A MX PA03008134A MX PA03008134 A MXPA03008134 A MX PA03008134A MX PA03008134 A MXPA03008134 A MX PA03008134A
Authority
MX
Mexico
Prior art keywords
compound
methyl
processes
producing
active ingredient
Prior art date
Application number
MXPA03008134A
Other languages
English (en)
Inventor
Shinsuke Hashimoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MXPA03008134A publication Critical patent/MXPA03008134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Se proporciona un compuesto N-fenilarilsulfonilamida de formula (I) (ver formula) (R1 es COOH, etc.; R2 es hidrogeno, metilo, etc.; R3 y R4 son una combinacion de metilo y metilo, etc; R5 es isopropilo, etc.; Ar es tiazolilo, piridilo, 5-metil-2-furilo, cada uno opcionalmente sustituido con metilo; n es cero o 1), un intermediario sintetico para el compuesto y un procedimiento para su preparacion. El compuesto de formula (I) se une a un receptor de prostaglandina E2, especialmente un receptor del subtipo EP1 y lo antagoniza. Es menos afectado por la union de proteinas de manera que tiene una actividad in vivo satisfactoria. Por lo tanto, se considera que es util como un analgesico, un agente antipiretico, un agente para el tratamiento de polakiuria (miccion frecuente) o el sindrome de enfermedad del tracto urinario inferior o un agente antineoplasico.
MXPA03008134A 2001-03-12 2002-03-11 Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion. MXPA03008134A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (fr) 2001-03-12 2002-03-11 Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production

Publications (1)

Publication Number Publication Date
MXPA03008134A true MXPA03008134A (es) 2004-03-10

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008134A MXPA03008134A (es) 2001-03-12 2002-03-11 Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.

Country Status (24)

Country Link
US (3) US7235667B2 (es)
EP (2) EP1369419B1 (es)
JP (3) JP3555620B2 (es)
KR (1) KR100886854B1 (es)
CN (1) CN1294126C (es)
AT (2) ATE522513T1 (es)
AU (1) AU2002238855B2 (es)
BR (1) BR0208027A (es)
CA (1) CA2439604C (es)
CZ (1) CZ304035B6 (es)
DE (1) DE60220255T2 (es)
DK (2) DK1612208T3 (es)
ES (1) ES2286230T3 (es)
HU (1) HU230056B1 (es)
IL (2) IL157701A0 (es)
MX (1) MXPA03008134A (es)
NO (1) NO329682B1 (es)
NZ (1) NZ528120A (es)
PL (1) PL218750B1 (es)
PT (2) PT1369419E (es)
RU (1) RU2299202C2 (es)
TW (1) TWI317359B (es)
WO (1) WO2002072564A1 (es)
ZA (1) ZA200306884B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264388A1 (en) * 2002-09-09 2004-03-29 Ono Pharmaceutical Co., Ltd. Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide
CN100408570C (zh) * 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
WO2005000356A1 (ja) * 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. 尿路疾患治療剤
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1767208A4 (en) * 2004-07-05 2007-12-05 Chugai Pharmaceutical Co Ltd REMEDY FOR HYPERACTIVE BLADDER
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
MX2009008606A (es) * 2007-02-16 2009-09-16 Ono Pharmaceutical Co Agente terapeutico para trastorno de excrecion urinaria.
WO2009017219A1 (ja) * 2007-08-01 2009-02-05 Taisho Pharmaceutical Co., Ltd. Ｓ１ｐ1結合阻害物質
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CA2728511A1 (en) * 2008-06-23 2009-12-30 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
EP2598481B1 (en) * 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
DK3138633T3 (en) * 2014-04-30 2019-03-18 Ind Penalver Sl Programmable concentric head for applying liquid to lids with different designs
MX2018005940A (es) * 2015-11-13 2018-08-14 Dae Woong Pharma Bloqueador del canal de sodio.
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (es) * 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) * 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (fr) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
EP1201238A4 (en) 1999-07-29 2003-01-15 Ono Pharmaceutical Co SULPHONAMIDE DERIVATIVES AND HEALING AGENTS FOR ALLODYNIA
CA2440374A1 (en) * 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient

Also Published As

Publication number Publication date
DK1369419T3 (da) 2007-09-24
CA2439604A1 (en) 2002-09-19
JP4432051B2 (ja) 2010-03-17
HU230056B1 (hu) 2015-06-29
JP3741120B2 (ja) 2006-02-01
AU2002238855B2 (en) 2007-12-06
RU2003127677A (ru) 2005-03-27
KR100886854B1 (ko) 2009-03-05
EP1612208A2 (en) 2006-01-04
IL157701A (en) 2010-06-30
HUP0400155A2 (hu) 2004-08-30
US7629369B2 (en) 2009-12-08
DK1612208T3 (da) 2011-12-12
IL157701A0 (en) 2004-03-28
ATE522513T1 (de) 2011-09-15
CN1509278A (zh) 2004-06-30
PL365100A1 (en) 2004-12-27
US8088802B2 (en) 2012-01-03
US7235667B2 (en) 2007-06-26
PL218750B1 (pl) 2015-01-30
EP1369419A4 (en) 2005-03-16
US20050124672A1 (en) 2005-06-09
NO329682B1 (no) 2010-11-29
EP1369419B1 (en) 2007-05-23
EP1369419A1 (en) 2003-12-10
US20060030713A1 (en) 2006-02-09
US20100041708A1 (en) 2010-02-18
BR0208027A (pt) 2004-12-28
CZ20032452A3 (cs) 2003-11-12
EP1612208B1 (en) 2011-08-31
PT1369419E (pt) 2007-08-16
CA2439604C (en) 2012-05-01
DE60220255D1 (de) 2007-07-05
NO20034007D0 (no) 2003-09-10
KR20030082978A (ko) 2003-10-23
PT1612208E (pt) 2011-10-12
ZA200306884B (en) 2005-03-30
JPWO2002072564A1 (ja) 2004-07-02
JP3555620B2 (ja) 2004-08-18
ATE362924T1 (de) 2007-06-15
RU2299202C2 (ru) 2007-05-20
ES2286230T3 (es) 2007-12-01
JP2006028193A (ja) 2006-02-02
EP1612208A3 (en) 2006-12-06
NZ528120A (en) 2006-05-26
DE60220255T2 (de) 2008-01-17
NO20034007L (no) 2003-11-12
HUP0400155A3 (en) 2007-05-02
JP2004149545A (ja) 2004-05-27
CZ304035B6 (cs) 2013-08-28
CN1294126C (zh) 2007-01-10
WO2002072564A1 (fr) 2002-09-19
TWI317359B (en) 2009-11-21

Similar Documents

Publication Publication Date Title
MXPA03008134A (es) Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.
EP1312601A4 (en) CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
GEP20105082B (en) (biphenyl) carboxylic acids and derivatives thereof
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
YU37203A (sh) Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti
JP2005526696A5 (es)
EP1582521A4 (en) CONDENSED FURANE COMPOUND
YU50302A (sh) Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
EP1314719A4 (en) BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
EP1591441A4 (en) CARBON ACID COMPOUNDS
ATE496028T1 (de) Piperidinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
FI964303A0 (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
ATE294780T1 (de) Arylpiperidin- und aryl-1,2,5,6- tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
TR200101901T2 (tr) 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler
AU1434201A (en) Antithrombotic agents
TH65078A (th) อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล

Legal Events

Date Code Title Description
FG Grant or registration